案例报告:通过CyDRI协议有效管理阿达利木马布诱导的获得性血友病A
Andrea Ceglédi1,2,3, Árpád Bátai4, János Dolgos1
1Departments of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary.
治疗类风湿性关节炎的阿达利穆马布治疗很少会导致获得的血友病A (AHA),一种严重的出血障碍. 及时评估和使用诸如重组因子VIIa之类的药物治疗对于管理这种情况至关重要.
科学领域:
- 类风湿病学 类风湿病学
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 获得性血友病A (AHA) 是一种罕见的自身免疫性疾病,涉及对凝血因子VIII的抑制剂,导致严重出血.
- 作为TNF抑制剂的Adalimumab用于类风湿性关节炎,但在罕见情况下可以诱导AHA.
更多相关视频
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
